Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Recombinant human complement factor H - Eleva

Next Previous
Drug Profile

Recombinant human complement factor H - Eleva

Alternative Names: Compleva FH; CPV-104

Latest Information Update: 24 Sep 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Eleva
  • Class Eye disorder therapies; Recombinant proteins; Urologics
  • Mechanism of Action Complement factor H replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Membranoproliferative glomerulonephritis
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase I/II Membranoproliferative glomerulonephritis
  • Preclinical Dry age-related macular degeneration

Most Recent Events

  • 11 Jun 2025 Phase-I/II clinical trials in Membranoproliferative glomerulonephritis in Germany (Intravitreous) (CTIS2024-517992-19-00) (EUCT2024-517992-19-00)
  • 04 Feb 2025 Eleva plans a phase I clinical trial in Membranoproliferative glomerulonephritis in H1 2025 (Parenteral)
  • 04 Feb 2025 Preclinical trials in Dry age-related macular degeneration in Germany (Intravitreous)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top